High Tide's German Subsidiary Sets New Distribution Record

High Tide's German subsidiary, Remexian, reported a 62% YoY increase in medical cannabis distribution to a record 10.2 tons in Q3 2026. The segment's revenue reached $38.2 million with a gross margin of 26%. Since High Tide's acquisition, Remexian's market share in Germany has risen from 6.5% to 10.5%. The company attributes its success to its Canadian supply relationships, a competitive advantage in the expanding German medical market.